Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6732091 | 0.91 | PPARG (0.45) | PPARGPPARAOPRK1PPARDNR1H2 | |
| SCHEMBL6728310 | 0.89 | PPARG (0.44) | PPARGPPARAOPRK1PPARDNR1H2 | |
| SCHEMBL6787295 | 0.89 | OPRK1 (0.44) | PPARGPPARAOPRK1PPARDNR1H2 | |
| SCHEMBL6730895 | 0.88 | PPARG (0.42) | PPARGPPARAOPRK1PPARDNR1H2 | |
| SCHEMBL6728147 | 0.87 | PPARG (0.40) | PPARGPPARAOPRK1PPARDNR1H2 | |
| SCHEMBL6730443 | 0.82 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL6731216 | 0.82 | F10 (0.43) | OPRK1 | |
| SCHEMBL6733950 | 0.80 | PPARG (0.47) | PPARGPPARAPPARDPTGDR2 | |
| SCHEMBL6734035 | 0.77 | F10 (0.50) | — | |
| SCHEMBL6725335 | 0.74 | F10 (0.43) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | PPARG 1204/4885PPARA 573/4885OPRK1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.